Latest News and Press Releases

SAN ANTONIO, May 14, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Peter S....

SAN ANTONIO, March 01, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has been approved for membership in the Early Detection...

SAN ANTONIO, Texas, Jan. 05, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced that it will present its proprietary technology to detect...

SAN ANTONIO, Nov. 29, 2017 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced the appointments of Stephen Squinto, Ph.D., and...

SAN ANTONIO, July 19, 2017 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held company advancing early-stage cancer diagnostics and precision therapeutics, announced today that it raised...

SAN ANTONIO, June 28, 2017 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held company advancing early stage cancer diagnostics and precision cancer therapeutics, today announced four...

SAN ANTONIO, Texas, May 03, 2017 (GLOBE NEWSWIRE) -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath®...

SAN ANTONIO, March 09, 2017 (GLOBE NEWSWIRE) -- The San Antonio City Council today authorized the San Antonio Economic Development Corporation (SAEDC) to invest in locally based bioAffinity...

SAN ANTONIO, Nov. 15, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies announced that the government of the Hong Kong Special Administrative Region has awarded a Certificate of Grant of Standard...

SAN ANTONIO, Texas, Aug. 24, 2016 (GLOBE NEWSWIRE) -- bioAffinity Technologies today announced that it has been awarded a U.S. Patent protecting a proprietary kit that contains the...